Background
Scilex Pharmaceuticals exclusively licenses three patents covering non-aqueous lidocaine patches, while Itochu Chemical Frontier and Oishi Koseido own the patents. After Aveva Drug Delivery Systems sought FDA approval for a generic version of Scilex’s ZTlido topical patch, the plaintiffs sued, alleging infringement of dependent claim 4 of each patent.
The plaintiffs conceded that Aveva’s proposed product did not literally infringe. They instead argued under the doctrine of equivalents that the isostearic acid and oleyl alcohol in Aveva’s patch performed substantially the same function, in substantially the same way, to achieve substantially the same result as the claimed dissolving agent consisting of isostearic acid and dipropylene glycol. Following a four-day bench trial, the Southern District of Florida entered judgment of noninfringement.
The Court’s Holding
The Federal Circuit affirmed in a nonprecedential per curiam opinion. Reading the claims in light of the specification and prosecution history, the court held that the claimed “dissolving agent” must both dissolve the lidocaine and maintain it in a non-crystalline state in the finished patch. The specification repeatedly described the organic-acid-and-polyalcohol combination as dissolving lidocaine, and all six disclosed examples used that combination to dissolve the drug before it was mixed with adhesives.
The prosecution history reinforced that construction because Oishi repeatedly represented that the lidocaine was dissolved in the claimed organic acid and polyalcohol. Aveva, by contrast, used n-heptane as the single solvent that dissolved the lidocaine, and the district court found that n-heptane, alone or in combination with another component, was not equivalent to the claimed dissolving agent. The Federal Circuit therefore upheld noninfringement without reaching the district court’s alternative rulings that treating oleyl alcohol as equivalent to the claimed polyalcohol would vitiate specified claim limitations and that Oishi had clearly and unmistakably disclaimed dissolving agents other than one consisting essentially of an organic acid and a polyalcohol.
Key Takeaways
- A claimed “dissolving agent” had to perform two functions: dissolve the lidocaine and keep it non-crystalline in the finished patch.
- Repeated, consistent prosecution statements can inform claim meaning even if they do not independently establish an unmistakable disclaimer.
- Because Aveva used n-heptane—not the asserted equivalent components—to dissolve the lidocaine, the plaintiffs could not establish infringement under the adopted construction.
Why It Matters
The decision illustrates how the specification’s examples and an applicant’s repeated prosecution statements can define the functional requirements of a claim term. A patentee cannot necessarily broaden that term during infringement litigation to cover ingredients that preserve a dissolved state but do not perform the claimed dissolving function.
The court resolved the appeal on claim construction and the resulting failure of proof, leaving the district court’s claim-vitiation and disclaimer rulings unreviewed.